Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of SSGJ-627 in Healthy Adults
NCT07065136Phase 1Not yet recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing SSGJ-627 with Placebo (2 arms). Primary endpoint: Number of participants with Adverse Events at Day 99. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
SSGJ-627
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07065136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065136.